Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Plus Therapeutics ( (PSTV) ) just unveiled an update.
On May 16, 2025, Plus Therapeutics, Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days. This situation does not immediately affect the company’s stock listing or trading, but Plus Therapeutics has until November 12, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not achieved by this date, the company may qualify for an additional 180-day period to meet the requirement, potentially through measures like a reverse stock split. Failure to comply could result in delisting, although the company can appeal such a decision.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.
Plus Therapeutics is facing significant financial challenges with consistent losses and negative equity, which are major risks. While there are positive future growth prospects from clinical trials and strategic financing efforts, the stock remains risky due to its current financial instability.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 17,584,455
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.14M
Find detailed analytics on PSTV stock on TipRanks’ Stock Analysis page.